Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Explanation of the aboriginal artwork:
The aboriginal artwork used symbolises the connection to country and the circle shape shows the strong relationships amongst families and the aboriginal culture. The horse shoe shape design shown in front of the generic statement symbolises a woman and those enclosing a smaller horse shoe shape depicts a pregnant women. The smaller horse shoe shape in this instance represents the unborn child. The artwork shown before the specific statements within the document symbolises a footprint and demonstrates the need to move forward together in union.

Australian Aboriginal Culture is the oldest living culture in the world yet Aboriginal people continue to experience the poorest health outcomes when compared to non-Aboriginal Australians. In South Australia, Aboriginal women are 2-5 times more likely to die in childbirth and their babies are 2-3 times more likely to be of low birth weight. The accumulative effects of stress, low socio economic status, exposure to violence, historical trauma, culturally unsafe and discriminatory health services and health systems are all major contributors to the disparities in Aboriginal maternal and birthing outcomes. Despite these unacceptable statistics the birth of an Aboriginal baby is a celebration of life and an important cultural event bringing family together in celebration, obligation and responsibility. The diversity between Aboriginal cultures, language and practices differ greatly and so it is imperative that perinatal services prepare to respectively manage Aboriginal protocol and provide a culturally positive health care experience for Aboriginal people to ensure the best maternal, neonatal and child health outcomes.

Purpose and Scope of PPG
This guideline provides clinicians with information for managing uterine hypercontractility, including administration of emergency tocolysis.
Tocolysis for Uterine Hypercontractility

Flowchart I: Management of uterine hypercontractility (hyperstimulation)

Definition
- More than five contractions in 10 minutes OR
- Contractions lasting more than 2 minutes

Fetal heart rate normal
- Prostaglandins
  - Change maternal position
  - Commence or continue CTG monitoring
  - Monitor uterine activity and fetal heart rate
  - Notify coordinator and ask for medical review
  - IV access

Fetal heart rate abnormal
- Prostaglandins
  - Change maternal position
  - Oxygen at 8 L for duration of fetal compromise
  - Continuous CTG monitoring
  - Review by medical officer
  - Vaginal assessment – ARM if able
  - If Cervidil® in situ: remove pessary by pulling the withdrawal tape
  - If dinoprostone (PGE2) gel is used, consider manually removing the gel
  - Prepare and administer emergency tocolysis
  - Consider fetal scalp blood sampling (where possible and available)

- Oxytocin infusion
  - Change maternal position
  - Increase IV fluids
  - Continuous CTG
  - Decrease oxytocin infusion to previous rate
  - Monitor uterine activity and fetal heart rate
  - Notify coordinator and ask for medical review
  - If no change in hyperstimulation after 20 minutes halve infusion rate

- Hypercontractility +/- oxytocin infusion
  - Change maternal position
  - Oxygen at 8 L
  - Continuous CTG
  - Increase IV fluids
  - Review by medical officer
  - Vaginal assessment
  - Decrease or cease oxytocin infusion (as required)
  - Palpate the uterus to determine uterine response to management
  - Observe for improvement in fetal heart rate

If hypercontractility persists
- Emergency tocolysis
  - IV Salbutamol OR
  - IV Terbutaline OR
  - Sublingual GTN spray
- Fetal scalp blood sampling (where possible and available)
- Consider the need for caesarean section if fetal compromise persists despite emergency treatment
Summary of Practice Recommendations

Uterine hypercontractility refers to more than five contractions in 10 minutes or contractions lasting more than 2 minutes. Early recognition is essential as uterine hyperstimulation causes poor utero-placental perfusion. Adverse effects on the fetus can be avoided by minimising periods of hyperstimulation, removing/reducing hyperstimulation-producing medication and administering treatment in a timely manner. Maternal assessment during tocolysis treatment is essential due to known cardiovascular side effects.
# Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARM</td>
<td>Artificial rupture of the membranes</td>
</tr>
<tr>
<td>CTG</td>
<td>Cardiotocograph</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>L</td>
<td>Litre(s)</td>
</tr>
<tr>
<td>mg</td>
<td>Milligram(s)</td>
</tr>
<tr>
<td>mL</td>
<td>Millilitre(s)</td>
</tr>
<tr>
<td>mmHg</td>
<td>Millimetres of mercury</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Clinical Excellence</td>
</tr>
<tr>
<td>%</td>
<td>Percent</td>
</tr>
<tr>
<td>PGE₂</td>
<td>Prostaglandin E₂</td>
</tr>
<tr>
<td>RANZCOG</td>
<td>Royal Australian and New Zealand College of Obstetricians and Gynaecologists</td>
</tr>
<tr>
<td>i.e.</td>
<td>That is</td>
</tr>
<tr>
<td>TGA</td>
<td>Therapeutic Goods Administration</td>
</tr>
<tr>
<td>URL</td>
<td>Uniform resource locator</td>
</tr>
</tbody>
</table>
Tocolysis for Uterine Hypercontractility

Introduction

➢ Uterine hypercontractility (hyperstimulation) may occur spontaneously in labour; however, it is frequently associated with prostaglandin agents or oxytocin infusion (see induction of labour)

➢ A retrospective study found that administration of tocolytic treatment with β2-adrenergic drugs following PGE2 induced uterine hyperstimulation was successful in normalising uterine contractions and reversing fetal compromise within 5 minutes in 98% of cases.¹

➢ No evidence has been identified relating to the management of uterine hyperstimulation caused by induction with intravenous oxytocin.¹

Uterine hypercontractility (hyperstimulation)

➢ Uterine hypercontractility refers to more than five contractions in 10 minutes, or contractions lasting more than 2 minutes and may or may not be associated with fetal compromise.¹

➢ Early recognition is essential as uterine hyperstimulation causes poor utero-placental perfusion leading to a decrease in fetal oxygenation and eventually fetal compromise.²

➢ A raised uterine baseline pressure also contributes to reduced utero-placental perfusion. Sustained baseline pressures above 15 mmHg lead to fetal heart rate changes.²

➢ Prolonged use of maternal facial oxygen therapy may be harmful to the baby and should be avoided. There is no research evidence evaluating the benefits or risks associated with the short-term use of maternal facial oxygen therapy in cases of suspected fetal compromise.³

Management of uterine hypercontractility

➢ Employ emergency management measures
  ➢ Place the woman in left lateral position
  ➢ Ensure good intravenous (IV) access and give bolus of fluid as indicated
  ➢ Continuous electronic fetal monitoring and observe for signs of fetal compromise
  ➢ Administer oxygen via face mask at 8 litres/minute for the duration of fetal compromise if present
  ➢ Palpate uterus to determine response to management

➢ If emergency management measures fail, administer tocolysis

➢ Adverse effects on the fetus can be avoided by minimising periods of hyperstimulation and administering treatment in a timely manner
  ➢ Either salbutamol or terbutaline tocolysis may be administered
  ➢ Nitrolingual® pump spray may be given if salbutamol or terbutaline are not available (see below)

➢ In cases where fetal compromise is sustained despite the above emergency measures, consider need to expedite delivery
Tocolysis for Uterine Hypercontractility

Salbutamol tocolysis regimen

Indications

> Persistent uterine hypercontractility with fetal compromise
> Tocolysis before attempting external cephalic version for breech presentation < 37+6 weeks gestation

Contraindications

> A bolus dose of salbutamol is contraindicated in:
  > Cardiac disease
  > Hypertension
  > Hyperthyroidism

Relative contraindication

> Diabetes

<table>
<thead>
<tr>
<th>Obstetric salbutamol: 5 mL ampoule 5 mg / 5 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage and administration</td>
</tr>
<tr>
<td>&gt; Using a 1 mL syringe, draw up 0.25 mL (250 micrograms) of salbutamol</td>
</tr>
<tr>
<td>&gt; Add to a 10 mL syringe and make up to 10 mL with sodium chloride 0.9 % (25 micrograms per mL)</td>
</tr>
<tr>
<td>&gt; Give intravenous salbutamol slowly in 50 microgram boluses up to 250 micrograms in total (often 100 micrograms will be sufficient)</td>
</tr>
<tr>
<td>&gt; Ensure monitoring of maternal pulse whilst bolus doses are administered</td>
</tr>
<tr>
<td>&gt; Stop IV administration if maternal pulse &gt; 140</td>
</tr>
</tbody>
</table>

Side effects

> Fetal and maternal tachycardia, maternal hypotension, ventricular ectopics, supraventricular tachycardia, ventricular fibrillation, pulmonary oedema, hypoxia – secondary to increased oxygen demands +/- fluid shift in lungs, hyperglycaemia
Tocolysis for Uterine Hypercontractility

Terbutaline tocolysis regimen

Indications
> Persistent uterine hypercontractility with fetal compromise
> Tocolysis before attempting external cephalic version for breech presentation < 37+6 weeks gestation
> These are not TGA approved indications

Contraindications
> Sympathomimetic amine hypersensitivity

Relative contraindications
> Cardiac disease
> Hypertension
> Hyperthyroidism
> Diabetes

<table>
<thead>
<tr>
<th>Terbutaline: 1 mL ampoule 500 micrograms / 1 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage and administration</td>
</tr>
<tr>
<td>&gt; May be given subcutaneous or intravenous</td>
</tr>
<tr>
<td>Subcutaneous</td>
</tr>
<tr>
<td>&gt; Using a 1 mL syringe, draw up 0.5 mL (250 micrograms) of terbutaline and administer subcutaneously</td>
</tr>
<tr>
<td>Intravenous</td>
</tr>
<tr>
<td>&gt; Using a 1 mL syringe, draw up 0.5 mL (250 micrograms) of terbutaline</td>
</tr>
<tr>
<td>&gt; Add to a 10 mL syringe and make up to 10 mL with sodium chloride 0.9 % (25 micrograms per mL)</td>
</tr>
<tr>
<td>&gt; Give intravenous terbutaline slowly in 50 microgram boluses up to 250 micrograms in total (often 100 micrograms will be sufficient)</td>
</tr>
<tr>
<td>&gt; <strong>Ensure monitoring of maternal pulse whilst bolus doses are administered</strong></td>
</tr>
<tr>
<td>&gt; <strong>Stop IV administration if maternal pulse &gt; 140</strong></td>
</tr>
</tbody>
</table>

Side effects
> Tremor, headache, nervousness, cardiovascular effects including arrhythmia, tachycardia, palpitation, muscle cramps, hypokalaemia
Tocolysis for Uterine Hypercontractility

Sublingual glyceryl trinitrate spray (Nitrolingual®)

> Nitrolingual® pump spray is a metered dose spray that delivers glyceryl trinitrate 400 micrograms per spray emission

Action

> The principal pharmacological action of glyceryl trinitrate is relaxation of vascular smooth muscle, producing a vasodilator effect on both peripheral arteries and veins, with more prominent effects on the latter

Indications

> Persistent uterine hypercontractility associated with fetal compromise (not a TGA approved indication)

Contraindications

> Acute circulatory failure (shock, circulatory collapse)
> Cardiac disease
> Pronounced hypotension (systolic BP < 90 mm Hg)
> Severe anaemia

Dosage and administration

> 1 metered spray (400 micrograms) administered as spray droplets beneath the tongue (do not inhale)
> Repeat after 5 minutes if hypertonus sustained
> No more than 2 metered doses should be given

Administration

> Nitrolingual pump spray should be primed before using it for the first time by pressing the nozzle five times
> If Nitrolingual pump spray has not been used for seven days a priming of one spray will be necessary
> If the product has not been used for more than four months it will need to be primed several times (maximum five) until an even spray is obtained
> The woman should be in a sitting position
> The bottle should be kept vertical with the nozzle head uppermost
> Hold the opening in the nozzle head as close to the open mouth as possible and spray under the tongue
> Close the mouth immediately after each dose

Side effects

> Headache
> Hypotension
> Reflex tachycardia or bradycardia
> Rarely nausea, vomiting, flushing
References


Useful Resources


Tocolysis for Uterine Hypercontractility

Acknowledgements

The South Australian Perinatal Practice Guidelines gratefully acknowledge the contribution of clinicians and other stakeholders who participated throughout the guideline development process particularly:

Write Group Lead

Allison Rogers
Dr Brian Peat
Catherine Leggett

Write Group Members

Dr Peter Muller

Other major contributors

SAPPG Work Group 2004-2014

SAPPG Management Group Members

Sonia Angus
Dr Kris Bascomb
Lyn Bastian
Elizabeth Bennett
Dr Feisal Chenia
John Coomblas
A/Prof Rosalie Grivell
Dr Sue Kennedy-Andrews
Jackie Kitschke
Catherine Leggett
Dr Anupa Parange
Dr Andrew McPhee
Rebecca Smith
A/Prof John Svigos
Dr Laura Willington
Tocolysis for Uterine Hypercontractility

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: HealthCYWHSPerinatalProtocol@sa.gov.au
Endorsed by: SA Health Safety and Quality Strategic Governance Committee
Next review due: 30 June 2019
ISBN number: 978-1-74243-301-1
PDS reference: CG155

Policy history:
- Is this a new policy (V1)? N
- Does this policy amend or update an existing policy? Y
- If so, which version? V3
- Does this policy replace another policy with a different title? N
- If so, which policy (title)?

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 May 2015</td>
<td>V3.1</td>
<td>SA Health Safety &amp; Quality Strategic Governance Committee</td>
<td>Review date extended to 5 years following risk assessment. New template.</td>
</tr>
<tr>
<td>10 Jun 2014</td>
<td>V3</td>
<td>SA Health Safety &amp; Quality Strategic Governance Committee</td>
<td>Reviewed</td>
</tr>
<tr>
<td>12 Apr 2011</td>
<td>V2</td>
<td>South Australian Maternal &amp; Neonatal Clinical Network</td>
<td>Reviewed in line with scheduled review date</td>
</tr>
</tbody>
</table>